The relationship between thiol-disulfide balance and prostate cancer
Medicine Science, cilt.9, sa.3, ss.779-783, 2020 (TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 9 Sayı: 3
- Basım Tarihi: 2020
- Doi Numarası: 10.5455/medscience.2020.04.046
- Dergi Adı: Medicine Science
- Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.779-783
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
This study aimed to investigatethe possible association of thiol/disulfidehomeostasiswith prostate-specific antigen levelsin prostate cancer patients and to compare theresults with a normal healthy population ofa similar age group for the first time in literature. Forty-twopatients (20 patientswith prostate cancer and 22 volunteers) wereincluded in the study. Thiol/disulfide homeostasis tests were measured with an automated method. Albumin, carcinoembryonic antigen (CEA), prostate-specific antigen(PSA), ischemia modified albumin (IMA), total thiol (TT), native thiol (–SH), and disulfide (–S–S–) levelsand, thiol-disulfide ratios (disulfide / native thiol, disulfide/totalthiol and native thiol/total thiol) were assessed to detect any differences between prostate cancer group and control group. The mean PSA value of the prostate cancer groupwas 2.56 ng/mL, the mean PSA value of the control group was 1.21 ng/mL, and the mean age of the prostate cancer group was 67.32 years, the mean age of control groupwas 60.09. Although native thiol and total thiol levels were significantly lower in patients with prostate cancer (p<0.05), there was no difference between the other values(PSA, IMA, Albumin, CEA,–S–S– and thiol-disulfide ratios) in the prostate cancer group compared to the control group (p> 0.05). In our study, we could not show thiol-disulfide values as a biochemical prognostic factor in patients with prostate cancer. We believe that serum TT, –SH, –S–S– concentrations cannot serve as a noninvasivebiomarker for prostate cancer. To verify the biochemical role of thiol/disulfide balance, studies need to be done by increasing the number of patients with prostate cancer.